Literature DB >> 11294389

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.

G Chiosis1, N Rosen, L Sepp-Lorenzino.   

Abstract

Several LY294002-GM heterodimers were synthesized with the intent of modulating their activity in the presence of hsp90 and thereby creating selective inhibitors of PI3K and PI3K-related family.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11294389     DOI： 10.1016/s0960-894x(01)00099-3

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Heat shock proteins as emerging therapeutic targets.

Authors:  Csaba Sõti; Enikõ Nagy; Zoltán Giricz; László Vígh; Péter Csermely; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues.

Authors:  Lata T Gooljarsingh; Christine Fernandes; Kang Yan; Hong Zhang; Michael Grooms; Kyung Johanson; Robert H Sinnamon; Robert B Kirkpatrick; John Kerrigan; Tia Lewis; Marc Arnone; Alastair J King; Zhihong Lai; Robert A Copeland; Peter J Tummino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

3.  Thermodynamic Analysis of the Geldanamycin-Hsp90 Interaction in a Whole Cell Lysate Using a Mass Spectrometry-Based Proteomics Approach.

Authors:  Yingrong Xu; M Ariel Geer Wallace; Michael C Fitzgerald
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-16       Impact factor: 3.109

4.  TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation.

Authors:  Corey L Pelletier; Leonard B Maggi; Suzanne N Brady; Danielle K Scheidenhelm; David H Gutmann; Jason D Weber
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

Review 5.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition.

Authors:  Cheree Fitzgibbon; Saleh Ihmaid; Jasim Al-Rawi; Terri Meehan-Andrews; Christopher Bradley
Journal:  Invest New Drugs       Date:  2013-09-22       Impact factor: 3.850

7.  17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma.

Authors:  Shivendra Singh; Ahmed Abu-Zaid; Wenwei Lin; Jonathan Low; Alireza Abdolvahabi; Hongjian Jin; Qiong Wu; Bailey Cooke; Jie Fang; John Bowling; Sivaraja Vaithiyalingam; Duane Currier; Mi-Kyung Yun; Dinesh M Fernando; Julie Maier; Heather Tillman; Purva Bulsara; Zhaohua Lu; Sourav Das; Anang Shelat; Zhenmei Li; Brandon Young; Richard Lee; Zoran Rankovic; Andrew J Murphy; Stephen W White; Andrew M Davidoff; Taosheng Chen; Jun Yang
Journal:  iScience       Date:  2020-12-28

8.  Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Authors:  B P Nutley; N F Smith; A Hayes; L R Kelland; L Brunton; B T Golding; G C M Smith; N M B Martin; P Workman; F I Raynaud
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.